Citation Impact
Citing Papers
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
2014 Standout
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve
2011 Standout
Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green
2018 StandoutNobel
Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses
2007
Functional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology
2011
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
2008
Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
2009
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment
2015
Stress, sex hormones, inflammation, and major depressive disorder: Extending Social Signal Transduction Theory of Depression to account for sex differences in mood disorders
2019
The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial
2009
Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression
2016
Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression
2009
Deep Convolutional Neural Networks Enable Discrimination of Heterogeneous Digital Pathology Images
2017
Depression
2018 Standout
From stress to inflammation and major depressive disorder: A social signal transduction theory of depression.
2014 Standout
Human Epidermal Growth Factor Receptor 2 Testing in Primary Breast Cancer in the Era of Standardized Testing: A Canadian Prospective Study
2014
Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors
2013
Is Depression an Inflammatory Disorder?
2011
Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations
2014
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
2009 Standout
Her2/neu Status Determination in Breast Cancer
2016
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
The inflammasome: Pathways linking psychological stress, depression, and systemic illnesses
2012
Idiopathic pulmonary fibrosis
2017 Standout
Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer
2011
Psoriasis
2009 Standout
The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results
2008 Standout
Research gaps in psoriasis: Opportunities for future studies
2013
Chronic Gastrointestinal Inflammation Induces Anxiety-Like Behavior and Alters Central Nervous System Biochemistry in Mice
2010
Antidepressant effects of TNF-α blockade in an animal model of depression
2013
Mechanisms of cytokine-induced behavioral changes: Psychoneuroimmunology at the translational interface
2008
Chronic inflammation in the etiology of disease across the life span
2019 Standout
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
2008 Standout
Delirium in elderly people
2013 Standout
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-α: relationship to CNS immune responses and depression
2009
Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression
2013
Psoriasis
2021 Standout
Fatigue and gene expression in human leukocytes: Increased NF-κB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue
2010
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
2013
mTOR at the nexus of nutrition, growth, ageing and disease
2020 Standout
Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association
2022 Standout
Depression, comorbidities and the TNF-α system
2008
The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines
2006
Reciprocal regulation of the neural and innate immune systems
2011
Inflammatory Biomarkers in Depression: An Opportunity for Novel Therapeutic Interventions
2011
Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer
2007
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
mTOR Signaling in Growth, Metabolism, and Disease
2017 Standout
Psoriasis
2015 Standout
Interleukin-17 and Type 17 Helper T Cells
2009 Standout
Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C
2011
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
2013 Standout
Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis
2012
Power failure: why small sample size undermines the reliability of neuroscience
2013 Standout
Cytokine, Sickness Behavior, and Depression
2009
Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
2012 Standout
A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression
2012
Immune system to brain signaling: Neuropsychopharmacological implications
2011
Eating ourselves to death (and despair): The contribution of adiposity and inflammation to depression
2010
Immunopathogenesis of Psoriasis
2007
A prospective evaluation of the directionality of the depression–inflammation relationship
2009
Major Depressive Disorder
2008 Standout
Microglia Promote Learning-Dependent Synapse Formation through Brain-Derived Neurotrophic Factor
2013 Standout
Cytokines and schizophrenia: Microglia hypothesis of schizophrenia
2009
Depression gets old fast: do stress and depression accelerate cell aging?
2010
Exercise Enhances Learning and Hippocampal Neurogenesis in Aged Mice
2005 Standout
Etanercept Treatment for Children and Adolescents with Plaque Psoriasis
2008
Inflammation, Glutamate, and Glia in Depression:A Literature Review
2008
Clustering of Depression and Inflammation in Adolescents Previously Exposed to Childhood Adversity
2012
Interferon-α effects on diurnal hypothalamic–pituitary–adrenal axis activity: relationship with proinflammatory cytokines and behavior
2008
AKT/PKB Signaling: Navigating the Network
2017 Standout
Inflammation-associated depression: From serotonin to kynurenine
2010
Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour
2012 Standout
Cancer-related fatigue—mechanisms, risk factors, and treatments
2014 Standout
Tumour necrosis factor-α inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxiety
2015
Depressive disorders and immunity: 20 years of progress and discovery
2007
Cerebral Microglia Recruit Monocytes into the Brain in Response to Tumor Necrosis Factorα Signaling during Peripheral Organ Inflammation
2009
The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder
2006
The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: A randomized clinical trial
2010
From inflammation to sickness and depression: when the immune system subjugates the brain
2007 Standout
A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: Exploring the causes of heterogeneity
2012
The molecular neurobiology of depression
2008 StandoutNature
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
2018 Standout
The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis
2011
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
2013
A critical review of human endotoxin administration as an experimental paradigm of depression
2009
The cancer genome
2009 StandoutNature
The role of inflammation in depression: from evolutionary imperative to modern treatment target
2015 Standout
The Role of Inflammation in the Pathophysiology of Depression: Different Treatments and Their Effects
2011
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
2012 Standout
The neurobiology of depression and antidepressant action
2012
Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis
2016
Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer
2014
Cloning and functional expression of cDNAs encoding human and rat pancreatic polypeptide receptors.
1996 StandoutNobel
Effect of Anti-inflammatory Treatment on Depression, Depressive Symptoms, and Adverse Effects
2014
IL-17 and Th17 Cells
2009 Standout
Marked decrease of neuropeptide Y Y2 receptor binding sites in the hippocampus in murine prion disease
1997 StandoutNobel
Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on Behavior
2011
Inflammatory Biomarkers and Fatigue during Radiation Therapy for Breast and Prostate Cancer
2009
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
2016 Standout
Natural product and natural product derived drugs in clinical trials
2014 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
CYTOKINE TARGETS IN THE BRAIN: IMPACT ON NEUROTRANSMITTERS AND NEUROCIRCUITS
2013
Chronic Antidepressant Treatment Increases Neurogenesis in Adult Rat Hippocampus
2000 Standout
Inflammation in Depression and the Potential for Anti-Inflammatory Treatment
2016
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
2020 Standout
EAT-4, a Homolog of a Mammalian Sodium-Dependent Inorganic Phosphate Cotransporter, Is Necessary for Glutamatergic Neurotransmission inCaenorhabditis elegans
1999 StandoutNobel
Works of Deepa Lalla being referenced
Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer
2007
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer
2014
Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer
2013
Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial
2005
Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial
2005
The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer
2015
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
2005
Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 status
2013
Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+ breast cancer
2006
Validation of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Symptom Index (FOSI) in a phase II clinical trial of pertuzumab in patients with advanced ovarian cancer
2007
P1-07-02: Discordance between Central and Local Laboratory HER2 Testing from a Large HER2−Negative Population in VIRGO, a Metastatic Breast Cancer Registry.
2011